Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Poly(epsilon-caprolactone) and Eudragit microparticles containing fludrocortisone acetate.

Stéphane Gibaud1, Najim Jabir Al Awwadi, Camille Ducki

  • 1Laboratoire de Pharmacie Clinique, UPRES EA 3452, Faculté de Pharmacie, 5, rue Albert Lebrun, Nancy 54000, France. stephane.gibaud@pharma.uhp-nancy.fr

International Journal of Pharmaceutics
|January 7, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The scientific controversy is essential.

Annales pharmaceutiques francaises·2026
Same author

Transdermal delivery of lornoxicam <i>via</i> transethosomal gel as a novel strategy for management of rheumatoid arthritis.

Drug development and industrial pharmacy·2026
Same author

Leveraging knowledge for explainable AI in personalized cancer treatment: challenges and future directions.

Frontiers in digital health·2025
Same author

Can Napoleon's skin disease and treatment be identified from paleoproteomic analyses of his last bathtub (1821)?

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Unravelling the Role of Uncommon Hydrogen Bonds in Cyclodextrin Ferrociphenol Supramolecular Complexes: A Computational Modelling and Experimental Study.

International journal of molecular sciences·2023
Same author

Evaluation of drug cost savings related to clinical trials from the perspective of a university hospital.

European journal of hospital pharmacy : science and practice·2023

Developing sustained-release fludrocortisone (FLU) microparticles improves patient compliance for mineralocorticoid insufficiency. The S/O/W method with micronized FLU suspension achieved high incorporation efficiency and optimal drug release profiles.

Area of Science:

  • Pharmaceutical Technology
  • Drug Delivery Systems
  • Materials Science

Background:

  • Substitutive hormonal therapies require long-term administration, impacting patient compliance.
  • Sustained-release formulations, like microparticle suspensions, can reduce dosing frequency and side effects.

Purpose of the Study:

  • To compare different fludrocortisone microparticle formulations for mineralocorticoid insufficiency treatment.
  • To evaluate the impact of polymers and preparation methods on microparticle characteristics and drug release.

Main Methods:

  • Microparticles were prepared using poly(epsilon-caprolactone), Eudragit RS, and Eudragit RL polymers.
  • Both O/W and S/O/W solvent evaporation methods were employed.
  • Fludrocortisone incorporation efficiency and surface morphology were analyzed.

Related Experiment Videos

Main Results:

  • The S/O/W method using a micronized fludrocortisone suspension significantly improved incorporation efficiency (approx. 79%) compared to dissolved drug (5.8-7.3%).
  • S/O/W microparticles exhibited surface crystals, while dissolved drug formulations were smooth.
  • Optimal release profiles were achieved with microparticles prepared near drug saturation (7.5 mg/ml dichloromethane).

Conclusions:

  • The S/O/W method with micronized fludrocortisone suspension is a promising approach for developing effective microparticle formulations.
  • Polymer mixtures did not enhance release profiles compared to optimized single-component formulations.
  • Fludrocortisone microparticles offer potential for improved patient compliance in treating mineralocorticoid insufficiency.